
John M Pagel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/356912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology, 2023, 41, 555-567.	1.6	82
2	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naÃ ⁻ ve chronic lymphocytic leukemia. Leukemia, 2022, 36, 1171-1175.	7.2	72
3	Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncology, The, 2022, 23, 1021-1030.	10.7	15
4	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation, 2021, 56, 202-209.	2.4	6
5	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, 35, 3201-3211.	7.2	25
6	Umbralisib, a Dual PI3KÎ′/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2021, 39, 1609-1618.	1.6	111
7	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, JCO.20.01739.	1.6	10
8	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 2021, 137, 3327-3338.	1.4	47
9	Integrated safety analysis of umbralisib, a dual PI3KÎ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances, 2021, 5, 5332-5343.	5.2	13
10	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of Clinical Oncology, 2021, 39, 3853-3865.	1.6	115
11	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study. Lancet Haematology,the, 2021, 8, e912-e921.	4.6	32
12	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular Cancer Therapeutics, 2020, 19, 2575-2584.	4.1	7
13	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia. Blood Advances, 2020, 4, 1711-1721.	5.2	30
14	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 2020, 135, 1204-1213.	1.4	130
15	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet, The, 2020, 395, 1278-1291.	13.7	393
16	Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S283.	0.4	3
17	Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma. Clinical Cancer Research, 2019, 25, 6932-6938.	7.0	15
18	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clinical Cancer Research, 2019, 25, 4264-4270.	7.0	61

John M Pagel

#	Article	IF	CITATIONS
19	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances, 2019, 3, 1553-1562.	5.2	145
20	A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life. Blood, 2019, 134, 5892-5892.	1.4	0
21	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1018-1018.	1.4	6
22	Neighborhood imbalances: overcoming MCL drug resistance. Blood, 2016, 128, 2752-2753.	1.4	3
23	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood, 2016, 127, 352-359.	1.4	29
24	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2016, 374, 323-332.	27.0	785
25	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2016, 374, 311-322.	27.0	1,532
26	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. Blood, 2016, 128, 1166-1166.	1.4	5
27	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). Blood, 2016, 128, 3307-3307.	1.4	16
28	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4050-4050.	1.4	43
29	Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study. Blood, 2016, 128, 60-60.	1.4	40
30	Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study. Blood, 2016, 128, 638-638.	1.4	23
31	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 901-901.	1.4	42
32	Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology, 2016, 34, 7527-7527.	1.6	7
33	Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study. Blood, 2016, 128, 4396-4396.	1.4	1
34	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood, 2015, 125, 2111-2119.	1.4	52
35	Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood, 2015, 125, 2779-2785.	1.4	68
36	Quantitative singleâ€particle digital autoradiography with <i>α</i> â€particle emitters for targeted radionuclide therapy using the iQID camera. Medical Physics, 2015, 42, 4094-4105.	3.0	48

JOHN M PAGEL

#	Article	IF	CITATIONS
37	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and highâ€risk myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 483-486.	4.1	21
38	α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After ²¹¹ At-Radioimmunotherapy for Hematopoietic Cell Transplantation. Journal of Nuclear Medicine, 2015, 56, 1766-1773.	5.0	18
39	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. Biology of Blood and Marrow Transplantation, 2015, 21, 373-378.	2.0	30
40	Long-Term Outcomes of Patients with Persistent Indolent BÂCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
41	Brentuximab vedotin administered to platinumâ€refractory, transplantâ€naÃ⁻ve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematological Oncology, 2015, 33, 187-191.	1.7	10
42	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. Blood, 2015, 126, 254-254.	1.4	61
43	Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3794-3794.	1.4	8
44	Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas. Blood, 2015, 126, 2728-2728.	1.4	0
45	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies. Cancer Research, 2014, 74, 1179-1189.	0.9	45
46	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1363-1368.	2.0	54
47	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). Leukemia Research Reports, 2013, 2, 26-28.	0.4	2
48	Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood, 2013, 121, 3759-3767.	1.4	59
49	A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL). Blood, 2013, 122, 4191-4191.	1.4	1
50	Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 (211At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model. Blood, 2013, 122, 5139-5139.	1.4	0
51	A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2013, 122, 3926-3926.	1.4	1
52	Bendamustine (Treanda®)-Based Regimens Are Effective In Mobilizing Peripheral Blood Hematopoietic Stem Cells For Autologous Transplantation. Blood, 2013, 122, 2033-2033.	1.4	0
53	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 1317-1317.	1.4	0
54	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood, 2012, 120, 304-304.	1.4	18

John M Pagel

#	Article	IF	CITATIONS
55	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Blood, 2012, 120, 4164-4164.	1.4	3
56	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. Blood, 2012, 120, 655-655.	1.4	0
57	A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma. Blood, 2012, 120, 811-811.	1.4	0
58	Anti-CD45 Radioimmunotherapy Using the Alpha-Emitting Radionuclide 211At Combined with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model. Blood, 2012, 120, 4096-4096.	1.4	0
59	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Blood, 2012, 120, 1924-1924.	1.4	0
60	Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model. Blood, 2012, 120, 4101-4101.	1.4	0
61	Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF) Blood, 2012, 120, 2499-2499.	1.4	0
62	Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. Blood, 2012, 120, 3594-3594.	1.4	1
63	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood, 2010, 116, 4231-4239.	1.4	63
64	Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 2009, 114, 5444-5453.	1.4	161
65	Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts Blood, 2007, 110, 330-330.	1.4	4
66	Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells Blood, 2007, 110, 499-499.	1.4	1
67	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen Blood, 2007, 110, 1905-1905.	1.4	0
68	131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood, 2006, 107, 2184-2191.	1.4	146
69	Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood, 2006, 108, 328-336.	1.4	47
70	Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid Acyltransferase-Â and Anti-CD20 Monoclonal Antibodies for Treatment of Human Non-Hodgkin's Lymphomas. Clinical Cancer Research, 2005, 11, 4857-4866.	7.0	32
71	Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin's Lymphoma Blood, 2005, 106, 2081-2081.	1.4	1
72	A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML) Blood, 2004, 104, 828-828.	1.4	2

#	Article	IF	CITATIONS
73	Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood, 2003, 101, 2340-2348.	1.4	103